Under the terms of this pharma partners agreement, EOS will receive a €45 million upfront payment, and Servier will obtain an exclusive license covering the world with the exception of the United States, Japan and China.
In addition, for an undisclosed amount, EOS will receive clinical and registration milestones as well as royalties.
The pharma partners alliance will actively build on the promising results of the Phase I-IIa Study, especially regarding the treatment of breast cancer.
E-3810 is a novel kinase inhibitor targeting efficiently both Fibroblast Growth Factor Receptor 1 (FGFR1) and Vascular Endothelial Growth Factor
E-3810 through Phase II-III studies while retaining commercial rights for important oncological markets.
For further deal information visit Current Agreements (subscription required)
Read: more on partnering deals in pharma, biotech, life science partnering deal news, insights and glossary
Related reports: Oncology Partnering Terms and Agreements
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity